The newly diagnosed RET-mutated MTC cases gained two FDA-approved therapies, which have been shown to have major efficacy as measured by improved overall response rate (ORR) and duration of response in the LIBRETTO-121 and ARROW trials76,77. Here, RET is linked to medullary thyroid gland carcinoma.